Mankind Pharma , a leading pharmaceutical company in India, has expressed confidence in the stability of its anti-diabetic drug portfolio despite the growing popularity of GLP-1 therapies. The company's CEO, Sheetal Arora, highlighted the strong performance of chronic therapies in the latest quarter, with both cardiology and anti-diabetes segments showing 1.5 times growth.

Resilient Anti-Diabetic Portfolio

Arora stated that the company expects to maintain its position in the anti-diabetes market, even as new treatments emerge. He emphasized the strength of Mankind Pharma's mature brands and its positioning across multiple therapy areas as key factors contributing to this confidence. Arora noted, "Traditional molecules typically don't disappear from the market when new treatments emerge," suggesting that the company's established products are likely to retain their relevance.

Strong Financial Performance

For the quarter under review, Mankind Pharma reported impressive financial results:

Dividend Announcement

In a move that may please shareholders, the board of Mankind Pharma has approved an interim dividend of Re 1 per share.

Corporate Governance Update

Mankind Pharma recently held its 34th Annual General Meeting (AGM). During the meeting, shareholders approved several key resolutions, including:

1. Adoption of the audited financial statements for the fiscal year
2. Re-appointment of Mr. Sheetal Arora as a director
3. Appointment of M/s. Amit Gupta & Associates as the company's Secretarial Auditors for a term of five years
4. Ratification of the remuneration for the Cost Auditor

The company has also appointed M/s. Amit Gupta & Associates, Company Secretaries, as its Secretarial Auditors for a five-year term, starting from the conclusion of the 34th AGM until the 39th AGM.

As Mankind Pharma continues to navigate the evolving pharmaceutical landscape, its strong performance in chronic therapies and confidence in its anti-diabetic portfolio position the company well for future growth. The management's optimism, coupled with strategic appointments and shareholder-friendly measures, suggests a focused approach to maintaining the company's market position in the competitive pharmaceutical industry.

Mankind Pharma Limited, a prominent player in the Indian pharmaceutical industry, has initiated steps to reclassify one of its promoter entities from the 'Promoter & Promoter Group' category to the 'Public' category. The company has submitted applications to both the BSE Limited and the National Stock Exchange of India Limited for this purpose.

Key Details of the Reclassification Request

Regulatory Compliance

The reclassification request has been made in accordance with Regulation 31A(3) of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. This move demonstrates Mankind Pharma's commitment to adhering to regulatory standards and maintaining transparency in its corporate structure.

Official Communication

In an official letter to the stock exchanges, Hitesh Kumar Jain, Company Secretary and Compliance Officer of Mankind Pharma Limited, stated:

"We wish to inform you that the Company has today, i.e., August 3, 2025, submitted an application with BSE Limited and National Stock Exchange of India Limited for reclassification of Ayushi and Poonam Estates LLP from the 'Promoter & Promoter Group' category to the 'Public' category, pursuant to the provisions of Regulation 31A(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015."

Implications and Next Steps

The reclassification, if approved by the stock exchanges and SEBI, could potentially alter the shareholding structure of Mankind Pharma. Investors and market watchers will be keen to observe any changes in the company's ownership pattern and its potential impact on corporate governance and decision-making processes.

As the application undergoes review by the regulatory authorities, stakeholders will await further updates on the progress of this reclassification request. The move underscores the dynamic nature of corporate structures in the pharmaceutical sector and the importance of regulatory compliance in India's capital markets.